 xml:space="preserve" bytes="2934"><!-- Please do not remove or change this AfD message until the issue is settled -->
{{Article for deletion/dated|page=Douglas D. Taylor|timestamp=20150713043856|year=2015|month=July|day=13|substed=yes|help=off}}
<!-- Once discussion is closed, please place on talk page: {{Old AfD multi|page=Douglas D. Taylor|date=13 July 2015|result='''keep'''}} -->
<!-- End of AfD message, feel free to edit beyond this point -->
{{BLP sources|date=July 2015}}
'''Douglas D. Taylor''' is an entrepreneur and former academic researcher in the field of [[Exosome (vesicle)|extracellular vesicles]]. Taylor is the Chief Scientific Officer of [[Aethlon Medical]] and its wholly-owned subsidiary, [[Exosome Sciences, Inc]].<ref>{{Cite web |url=http://www.prnewswire.com/news-releases/aethlon-medical-announces-dr-douglas-taylor-as-chief-scientific-officer-of-exosome-sciences-inc-223601621.html| title=Aethlon Medical Announces Dr. Douglas Taylor as Chief Scientific Officer of Exosome Sciences, Inc.|website=PR Newswire}}</ref> Taylor previously held an academic position at the [[University of Louisville]] in Kentucky.<ref>{{Cite web|url=http://www.prnewswire.com/news-releases/aethlon-medical-appoints-douglas-taylor-to-exosome-sciences-advisory-board-69645782.html| title="Advisory Board"}}</ref> Taylor has been described as one of the first to report on [[Exosome (vesicle)|exosomes]] in cancer.<ref>{{Cite web |url=http://www.marketwatch.com/story/are-exosomes-the-next-pd-1-in-cancer-research-2014-04-30 |title="Are Exosomes the Next PD-1 in Cancer Research?"| website=MarketWatch}}</ref> An institutional research misconduct investigation into the research of Taylor and his wife, [[Cicek Gercel-Taylor]], was launched by the University of Louisville, resulting in a 2015 finding of falsification of figures in published work and retraction of a paper in the ''[[Journal of Immunology]]''.<ref name="Retraction">{{cite web |url=http://retractionwatch.com/2015/06/10/exosome-pioneers-paper-retracted-after-investigation-finds-multiple-falsified-figures/ |title=Exosome pioneer’s paper retracted after investigation finds “multiple” faked figures |last1=Katsnelson |first1=Alla |website=Retraction Watch}}</ref> Concerns about other aspects of Taylor's research have also been raised.<ref name="Retraction"/><ref>{{Cite web |url=https://pubpeer.com/publications/EF344AE091446A2669DA0E5D1AC709#fb31587 |title= Comment on "MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer"|website=PubPeer}}</ref> Taylor is editor of the ''[[Journal of Glycobiology]]'' of [[OMICS Publishing Group|OMICS, Inc.]],<ref>www.omicsgroup.org/editor-biography/Douglas_Taylor/ OMICS Glycobiology biography</ref> a publisher on [[Jeffrey Beall|Beall's list]] of [[Predatory open access publishing|predatory open access publishers]].<ref>http://scholarlyoa.com/publishers/ Scholarly Open Access</ref>
==References==
{{reflist}}